GlassScriptPhysician profile
George Martin
NPI 1841222452
$16,142.72
in general payments reported to CMS, 2019-2025
37 companies · $444 in 2025
The $444 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,433 · 2020: $722 · 2021: $1,940 · 2022: $3,377 · 2023: $755 · 2024: $472 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350 · Education: $86.99 · Honoraria: $83.00 · Consulting Fee: $80.00 · Gift: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.42 |
| Education | $86.99 |
| Honoraria | $83.00 |
| Consulting Fee | $80.00 |
| Gift | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $6,176.65 | 2019-2024 | Xtandi |
| Pfizer INC. | $5,799.53 | 2019-2024 | |
| Genzyme Corporation | $1,970.62 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $527.54 | 2023-2025 | Gemtesa |
| Janssen Biotech, INC. | $259.06 | 2022-2025 | Erleada |
| Abbvie INC. | $159.91 | 2020-2025 | |
| Dendreon Pharmaceuticals LLC | $139.07 | 2019-2023 | Provenge |
| Medtronic, INC. | $120.00 | 2022-2023 | Endo Clip III, Surgipro Ll |
| C. R. Bard, INC. & Subsidiaries | $83.00 | 2024 | |
| Urovant Sciences INC | $75.77 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $73.38 | 2019-2025 | Adstiladrin |
| Sekisui Diagnostics LLC | $70.00 | 2023-2025 | |
| Boston Scientific Corporation | $66.45 | 2019-2025 | General - Bph |
| Urogen Pharma, INC. | $64.14 | 2025 | |
| Blue Earth Diagnostics | $48.09 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $42.56 | 2023-2024 | Da Vinci Surgical System |
| Novartis Pharmaceuticals Corporation | $41.74 | 2025 | |
| Myovant Sciences INC. | $39.60 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $35.72 | 2022 | |
| Photocure INC | $32.03 | 2019-2023 | Cysview |
| 180 Medical, INC. | $28.48 | 2024 | |
| Merck Sharp & Dohme LLC | $26.78 | 2023 | Lynparza, Keytruda |
| Dentsply Ih Ab | $24.27 | 2025 | Lofric |
| Tolmar Pharmaceuticals, INC. | $23.91 | 2022 | |
| Progenics Pharmaceuticals, INC. | $22.82 | 2024 | |
| Endo Pharmaceuticals INC. | $21.56 | 2022 | |
| Foundation Medicine, INC. | $20.02 | 2020 | |
| Axonics, INC. | $19.40 | 2023 | Bulkamid, Axonics |
| Dentsply Ih INC. | $18.17 | 2022 | |
| Baxter Healthcare | $18.13 | 2024 | Floseal |
| Astellas Pharma Global Development | $17.90 | 2020 | |
| Immunitybio, INC. | $16.18 | 2025 | |
| Zyla Life Sciences, INC. | $15.60 | 2020 | |
| Calyxo, INC. | $14.57 | 2022 | |
| Ethicon US, LLC | $14.23 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $10.82 | 2019 | |
| Healthtronics Stone Solutions, LLC | $5.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.